An interventional study of LINKED-HEARTS Program in Hypertension, High Blood Pressure and Diabetes, sponsored by Johns Hopkins University. Active, not recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Johns Hopkins University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Hypertension by Johns Hopkins University — 10 open to participants now, 14 under way, none of them phase 3. Hypertension · Johns Hopkins University.
Among the 50 studies in Hypertension by Johns Hopkins University, this one is the 12th largest by planned enrollment of the 44 interventional ones that give a count, is one of 4 that started in 2023, is one of 39 with no phase, reaches primary completion later than 1 of the 13 other live ones, and was the 32nd registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →10 of the 50 studies in Hypertension by Johns Hopkins University are open now, in 5 countries. Recruiting first, the newest first:
Johns Hopkins University · Sites in Bangladesh
Ages 18+
Johns Hopkins University · Sites in United States
Ages 21–70 · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 18–79 · Women only · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States, Ghana, Nigeria
Ages 18–70
By country, each count listing its studies:
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 425 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 138 across the 44 interventional studies, 50 across the 5 observational. Of the 33 that completed or were terminated, 8 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
Johns Hopkins University is the lead sponsor of 1,817 studies on the registry; 316 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
7 of the studies in Hypertension by Johns Hopkins University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607341Johns Hopkins UniversityCommunity Engagement Alliance Against Disparities | 2026-12-20 |
| NCT06921356Johns Hopkins UniversityGroceries Plus Multi-Component Lifestyle Intervention for Adults With Hypertension and Type 2 Diabetes | 2027-03-31 |
| NCT07909161Johns Hopkins UniversityTeam-Based Shared Decision-Making Program in Hypertension Control (Healthy Heart - BP Program) | 2027-03-31 |
| NCT07460882Johns Hopkins UniversityThe Impact of Low Sodium Salt Substitute Use on Serum Potassium Levels Among Patients With Hypertension | 2027-03-31 |
| NCT05703386Johns Hopkins UniversityImaging the Pathogenesis of Cerebral Small Vessel Disease | 2027-03-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 50 studies in Hypertension by Johns Hopkins University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The LINKED- HEARTS Program is a multi-level project that intervenes at the practice level by linking home blood pressure monitoring (HBPM) with a telemonitoring platform (Sphygmo). The program incorporates team-based care by including community health workers (CHWs) and pharmacists to improve the outcomes of multiple chronic conditions (reduced blood pressure (BP), lower blood sugar, and improved kidney function). The LINKED-HEARTS Program will recruit a total of 600 adults with uncontrolled hypertension (BP ≥ 140/90 mm Hg) AND either type 2 diabetes or chronic kidney disease (CKD) across 16 community health centers or primary care practices serving high-risk adults. This cluster-randomized trial consists of two arms: (1) enhanced "usual care arm," wherein patients will be provided with Omron 10 series home BP monitors and will be managed by the patients' primary care clinicians as usual; and (2) the "intervention arm" which will integrate HBPM telemonitoring, a CHW intervention and provider-level interventions into the usual clinical care to improve BP control and provide support for self-management of chronic conditions. The study pharmacist will conduct telehealth, use the Sphygmo app and the Pharmacist Patient Care Process to collaborate with other providers to optimize pharmacologic therapy to improve hypertension outcomes and with payors to ensure consistent access to drug therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in the LINKED-HEARTS Program will be trained to measure their blood pressure with an Omron 10 series device using the Sphygmo telemonitoring app. The physician, pharmacist and Community Health Worker will have access to transmit data. Community Health Workers will provide education on managing blood pressure; reinforce positive blood pressure self-management behaviors; deliver knowledge and skills to promote healthy chronic conditions; assist with linking clinical and administrative services; and link participants with community resources. The study pharmacist will conduct telehealth visits, optimize pharmacologic therapy. The pharmacists will assess and address medication adherence to improve hypertension and diabetes control.
Behavioral: LINKED-HEARTS Program
Patients in the Enhanced Usual Care Arm, will receive care as usual from their primary care provider and will be trained to measure their blood pressure with an Omron 10 series device. The staff in each participating community health center practice will be trained in blood pressure measurement best practices.
The intervention arm will include training on home blood pressure monitoring, Sphygmo blood pressure telemonitoring app, Community Health Worker visit for education, counseling on lifestyles modification and Pharmacist to collaborate with other providers to optimize pharmacologic therapy to improve hypertension outcomes and with payors to ensure consistent access to drug therapy.
Blood Pressure Control as assessed by percentage of participants with controlled Blood Pressure
Percent of patients with controlled Blood Pressure (\<140/90 mm Hg).
Time frame: 12 months
Change in Systolic Blood Pressure
Change from baseline in mean systolic blood pressure in millimeters of mercury (mmHg).
Time frame: Baseline and 12 months
Change in Diastolic blood pressure
Change from baseline in diastolic blood pressure in mmHg.
Time frame: Baseline and 12 months
Mean change in Hemoglobin A1c
Mean change from baseline in hemoglobin A1c (percent) in patients with a diagnosis of diabetes.
Time frame: Baseline and 12 months
Percent with Hemoglobin A1c < 7.0
Change from baseline in the percent with hemoglobin A1c \< 7.0 in patients with a diagnosis of diabetes.
Time frame: Baseline and 12 months
Change in Body Mass Index (BMI)
Change from baseline in BMI (Kg/m\^2).
Time frame: Baseline and 12 months
Mean change in Estimated Glomerular Filtration Rate
Mean change from baseline in Estimated Glomerular Filtration Rate.
Time frame: Baseline and 12 months
Change in Health-Related Quality of Life as assessed by the PROMIS 29
This outcome will be measured using Patient-Reported Outcomes Measurement Information System®, (PROMIS) 29 Profile v. 2.0
Time frame: 12 months and 24 months
Plan to share: No
Ran from Oct 2023 to primary completion in Sep 2026, 35 months.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 35 months is above that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Sep 2026, on Oct 13, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.